延长暴露疗法联合或不联合托吡酯治疗共病创伤后应激障碍与酒精使用障碍的随机临床试验
该双盲、安慰剂对照门诊试验将100名美国退伍军人(平均年龄45岁,84%为男性)随机分配至延长暴露疗法联合托吡酯(最高250 mg)或联合安慰剂,治疗16周。两组重度饮酒天数百分比均显著下降但组间无差异;治疗后评估时联合托吡酯组创伤后应激障碍评分低于联合安慰剂组,但随访时差异未维持。
要点
- 延长暴露疗法联合托吡酯组在治疗结束时创伤后应激障碍症状评分低于联合安慰剂组,但3个月和6个月随访时差异未维持。
- 两组重度饮酒天数百分比均显著下降,但组间无显著差异。
- 抑郁和生活质量等次要结局的变化在两组间无差异。
核心结论
- 延长暴露疗法联合托吡酯在积极治疗期间与创伤后应激障碍症状更大程度降低相关,但该效应在较长随访期未维持。
- 托吡酯对重度饮酒天数百分比或次要结局未显示对延长暴露疗法的额外获益。
研究设计与样本
- 双盲、安慰剂对照门诊临床试验,纳入100名美国退伍军人(平均年龄45岁,标准差12岁,84%为男性),随机分配至16周延长暴露疗法联合托吡酯(最高250 mg)或联合安慰剂。
主要发现
- 两组重度饮酒天数百分比均显著下降,但组间无差异。
- 治疗后评估时延长暴露疗法联合托吡酯组创伤后应激障碍评分低于联合安慰剂组,但随访时无差异。
- 创伤后应激障碍诊断丧失和有意义症状变化呈现相同模式。
- 抑郁和生活质量等次要结局的变化在两组间无差异。
临床怎么用
- 作者认为,加用托吡酯带来更快速和更显著的创伤后应激障碍症状减轻,可能对患者有益。
- 作者认为,由于托吡酯效应在较长随访期未维持,延长托吡酯使用时间或采取额外策略以延长此类效应可能有用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) frequently co-occur. Prolonged exposure (PE) is an effective treatment for PTSD but shows smaller effects in patients with co-occurring AUD. Topiramate may help reduce alcohol use and PTSD symptoms. This double-blind, placebo-controlled outpatient clinical trial compared 12 sessions of PE plus either topiramate or placebo. METHODS: One hundred U.S. veterans (mean age=45 years [SD=12], 84% men) with PTSD+AUD were randomly assigned to 16 weeks of treatment with PE+topiramate (up to 250 mg) or PE+placebo to examine effects on alcohol use and PTSD severity at posttreatment assessment and at 3- and 6-month follow-ups. RESULTS: Percent heavy drinking days decreased significantly for both conditions but did not differ between groups. PTSD scores were lower in the PE+topiramate group than in the PE+placebo group at posttreatment assessment, but not at follow-ups. The same patterns were observed for loss of PTSD diagnosis and meaningful PTSD symptom change. Change in secondary outcomes (depression, quality of life) did not differ between conditions. CONCLUSIONS: PE+topiramate was associated with a greater reduction in PTSD symptoms than PE+placebo during active treatment. The addition of topiramate led to more rapid and pronounced PTSD symptom reduction, which may be of benefit to patients. Because effects of topiramate were not maintained at longer-term follow-up, extending time on topiramate or additional strategies to prolong such effects may be useful. Topiramate did not show added benefit to PE for percent heavy drinking days or secondary outcomes.
引用
- Norman SB, Luciano MT, Panza KE, et al. A Randomized Clinical Trial of Prolonged Exposure Therapy With and Without Topiramate for Comorbid PTSD and Alcohol Use Disorder. Am J Psychiatry. 2025. PMID: 40103353. doi:10.1176/appi.ajp.20240470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。